Laboratorios Farmacéuticos ROVI

Edison Investment Research is terminating coverage on Laboratorios Farmacéuticos ROVI. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Small modular reactors – why governments and tech giants are embracing SMRs

Digital assets: Unlocking opportunities in listed blockchain equities

Hybrid Air Vehicles – Military options advance

Audiovisual

Latest

Waymap – executive interview

Herantis Pharma – executive interview

Take on Trusts – October 2025

About Edison

About Edison

Careers

Laboratorios Farmacéuticos ROVI (SP: ROVI)

Latest Insights

Laboratorios Farmacéuticos ROVI — 2021: A pinnacle year

Laboratorios Farmacéuticos ROVI — All good things come in threes

ROVI Laboratorios Farmaceuticos — Momentum continues across key franchises

Laboratorios Farmacéuticos ROVI — Top-line growth, significant margin expansion

Sector

Research

Laboratorios Farmacéuticos ROVI — Becat roll-out benefits top-line growth

Laboratorios Farmacéuticos ROVI — DORIA Phase III trial hits primary endpoint

Laboratorios Farmacéuticos ROVI — Outperforming the market

Laboratorios Farmacéuticos ROVI — Strength in heparins; next up DORIA

ROVI Laboratorios Farmaceuticos — Becat on track; guidance uplifted

Laboratorios Farmacéuticos ROVI — Top-line strength as R&D costs rise

ROVI Laboratorios Farmaceuticos — DORIA low risk, high reward

ROVI Laboratorios Farmaceuticos — Stunning growth in speciality pharmaceuticals

Laboratorios Farmacéuticos ROVI — Steady as she grows

ROVI Laboratorios Farmaceuticos — Biosimilar enoxaparin launches

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time